FEB 2 0 2001 Sheet 1 of Form PTO-1449 Attorney's Docket No. Application Serial No. 39766-0100 P1 10/633,008 & TRADEY INFORMATION DISCLOSURE STATEMENT Applicant(s) Avi ASHKENAZI, et al. Filing Date: Group Art Unit: (use several sheets if necessary) July 31, 2003 16414 表現事業 U.S.PATENT DOGUMENTS 学の多葉語 **多大型星**证证 Examiner Date Document No. Name **Filing Date** Class **Subclass** Initials No. (if appropriate) 04/01/86 4.579.827 Sakamoto et al. -436 536 WH MECENTERS AND THE SECOND PATENT DOCUMENTS EAST TO THE PROPERTY OF THE PROPERT Ref. Date Document No. Name Examiner Class Subclass **Translation** Initials No. YES 10/29/86 0 199 141 Europe **607K** MH 2. 15/00 3. 09/28/94 0 616 812 A1 Europe A61K 39/395 4m 09/28/94 0 616 812 B1 Europe A64K 39/395 HM OTHERIDOCUMENTS (including author, title, date (pertinent pages, etc.) Title Examiner Ref. Initials No. Boyum, A. "A One Stage Procedure for Isolation of Granulocytes and Lymphocytes from Human Blood," Norweigan 5.  $\mathcal{M}$ Defense Establishment, Div. Of Toxicology, pp. 51-76 Martin-Padura, I. et al, "Junctional Adhesion Molecule, aNovel Member of the Immunoglobulin Superfamily That 6.  $\mu J H$ Distributes at Intercellular Junctions and Modulates Monocyte Transmigration," J. Cell Biol. 142 (1): 117-27 (1998) Monks, A. et al., "Feasibility of High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cel 7. MH Lines," Natl. Cancer Inst. 83: 757-766 (1991) 8. Skehan, P. et al., "New Colorimetric Cytoxicity Assay for Anticancer-Drug Screening," J. Natl. Cancer Inst. 82: 1107-MH 1112 (1990) 9. Spencer, S. et al., "The Orphan Receptor CRF2-4 Is an Essential Subunit of the Interleukin 10 Recepto," J. Exp. Med. MH 187: 571-578 (1998). Taylor, S. et al., "The Human Homologue of Bub3 Is Required for Kinetochore Localization of Bub1 and a Mad3/Bub1-10. MM Related Protein Kinase," J. Cell. Biol. 142 (1): 1-11 (1998) Welt, S. et al., "Quantative Analysis of Antibody Localization in Human Metastatic Colon Cancer: A Phase I Study of 11. Monoclonal Antibody A33," J. Clin. Oncol. 8: 1894-1906 (1990) Welt, S. et al., "Phase I/II Study of Iodine 131-Labeled Monoclonal Antibody A33 in Patients with Advanced Colon 12. Cancer," J. Clin. Oncol. 12: 1561-1571 (1994)

EXAMINER: MG her Haddad DATE CONSIDERED: 5/2/05 EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant,

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2009086 v2

**EXAMINER** 

8 2005 8							
PTO-1449			ATTY. DOCKET NO.: 39766-0100P1	1	SERIAL NO.: 10/633,008		
			APPLICANT: Avi ASHKENAZI, et al.				
			FILING DATE: July 31, 20	GROUP: 1644			
		U.S	. PATENT DOCUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
MH	6,410,708	06/25/2002	Avi Askenazi et al.	<del>- 536</del>	23.5		
		FORE	EIGN PATENT DOCUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
mH	WO 00/29583 A2	5/25/2000	PCT	C12N	15/12		☒
	OTHER DO	CUMENTS (I	Including Author, Title, Date, P	ertinent Pa	ges, Etc.)		
mH	Martin-Padura et al., "Junctional Adhesion Molecule, A Novel Member of the Immunoglobin Superfamily that Distributes at Intercellular Junctions and Modulates Monocyte Transmigration", J. Cell Biology, Vol. 142, No. 1, pages 117-127, July 13, 1998.						
V.	Ozaki et al. "Cutting Edge: Combined Treatment of the TNF-alpha and IFN-gamma causes Redistribution of						

Junctional Adhesion Molecule in Human Endothelial Cells", J. Immunol., Vol. 163, No. 2, July 15, 1999.

DATE CONSIDERED 5/2/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.